Neuroinflammation and Alzheimer's Pathology in POCD
NCT05378659, Unknown, University of Tennessee Graduate School of Medicine
Trial 9
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
| Field | Value | Source |
|---|---|---|
| Title | Neuroinflammation and Alzheimer's Pathology in POCD | ClinicalTrials.gov |
| NCT number | NCT05378659 | ClinicalTrials.gov |
| Status | Unknown | ClinicalTrials.gov |
| Enrollment | 120 participants, estimated | ClinicalTrials.gov |
| Lead sponsor | University of Tennessee Graduate School of Medicine | ClinicalTrials.gov |
| Conditions | Post-Operative Confusion, Neuroinflammatory Response, Alzheimer Disease | ClinicalTrials.gov |
| Interventions | Montreal Cognitive Assessment, Stroop Test, 4AT Delirium, Grooved Pegboard, NACC Cognitive Battery, ERP Testing, Blood Plasma and Serum sampling, Cerebral Spinal Fluid Sample | ClinicalTrials.gov |
| First posted | 2022-05-18 | ClinicalTrials.gov |
| Last updated | 2022-05-18 | ClinicalTrials.gov |
Registered outcomes 42
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description | Source |
|---|---|---|---|---|
| Primary | Blood Interleukin-1 beta (IL-1β) | Baseline | A proinflammatory cytokine that activates astrocytes and micro ganglia | ClinicalTrials.gov |
| Primary | Blood Interleukin-1 beta (IL-1β) | Pre-op (pre-operation) -Visit 2- Day of surgery | A proinflammatory cytokine that activates astrocytes and micro ganglia | ClinicalTrials.gov |
| Primary | Blood Interleukin-1 beta (IL-1β) | Post-op Visit 2- In recovery room up to 12 hours post surgery | A proinflammatory cytokine that activates astrocytes and micro ganglia | ClinicalTrials.gov |
| Primary | Blood Interleukin-1 beta (IL-1β) | 2 Week Post-op -Visit 4 | A proinflammatory cytokine that activates astrocytes and micro ganglia | ClinicalTrials.gov |
| Primary | Blood Interleukin-1 beta (IL-1β) | 6 Week Post-op -Visit 5 | A proinflammatory cytokine that activates astrocytes and micro ganglia | ClinicalTrials.gov |
| Primary | Blood Tumor necrosis factor alpha (TNF- α) | Baseline | A proinflammatory cytokine associated with neuroinflammation associated with neurodegenerative diseases | ClinicalTrials.gov |
| Primary | Blood Tumor necrosis factor alpha (TNF- α) | Pre-op- Visit 2- Day of surgery | A proinflammatory cytokine associated with neuroinflammation associated with neurodegenerative diseases | ClinicalTrials.gov |
| Primary | Blood Tumor necrosis factor alpha (TNF- α) | Post-op Visit 2- In recovery room up to 12 hours post surgery | A proinflammatory cytokine associated with neuroinflammation associated with neurodegenerative diseases | ClinicalTrials.gov |
| Primary | Blood Tumor necrosis factor alpha (TNF- α) | 2-week Post-op Visit 4 | A proinflammatory cytokine associated with neuroinflammation associated with neurodegenerative diseases | ClinicalTrials.gov |
| Primary | Blood Tumor necrosis factor alpha (TNF- α) | 6-week Post-op Visit 5 | A proinflammatory cytokine associated with neuroinflammation associated with neurodegenerative diseases | ClinicalTrials.gov |
| Primary | Blood Macrophage inflammatory protein-1 alpha (MIP-1alpha) | Baseline | A chemotactic cytokine which plays a role in the inflammatory process of Alzheimer's Disease | ClinicalTrials.gov |
| Primary | Blood Macrophage inflammatory protein-1 alpha (MIP-1alpha) | Pre-op Visit 2- Day of surgery | A chemotactic cytokine which plays a role in the inflammatory process of Alzheimer's Disease | ClinicalTrials.gov |
| Primary | Blood Macrophage inflammatory protein-1 alpha (MIP-1alpha) | Post-op Visit 2- In recovery room up to 12 hours post surgery | A chemotactic cytokine which plays a role in the inflammatory process of Alzheimer's Disease | ClinicalTrials.gov |
| Primary | Blood Macrophage inflammatory protein-1 alpha (MIP-1alpha) | 2-week Post-op Visit 4 | A chemotactic cytokine which plays a role in the inflammatory process of Alzheimer's Disease | ClinicalTrials.gov |
| Primary | Blood Macrophage inflammatory protein-1 alpha (MIP-1alpha) | 6- week Post-op Visit 5 | A chemotactic cytokine which plays a role in the inflammatory process of Alzheimer's Disease | ClinicalTrials.gov |
| Primary | Blood Monocyte chemoattractant protein-1 (MCP-1/CCL2) | Baseline | A chemotactic cytokine which plays a role in the inflammatory process through the regulation of monocytes/macrophages | ClinicalTrials.gov |
| Primary | Blood Monocyte chemoattractant protein-1 (MCP-1/CCL2) | Pre-op Visit 2- Day of surgery | A chemotactic cytokine which plays a role in the inflammatory process through the regulation of monocytes/macrophages | ClinicalTrials.gov |
| Primary | Blood Monocyte chemoattractant protein-1 (MCP-1/CCL2) | Post-op Visit 2- In recovery room up to 12 hours post surgery | A chemotactic cytokine which plays a role in the inflammatory process through the regulation of monocytes/macrophages | ClinicalTrials.gov |
| Primary | Blood Monocyte chemoattractant protein-1 (MCP-1/CCL2) | 2 week Post-op Visit 4 | A chemotactic cytokine which plays a role in the inflammatory process through the regulation of monocytes/macrophages | ClinicalTrials.gov |
| Primary | Blood Monocyte chemoattractant protein-1 (MCP-1/CCL2) | 6 week- Post-op Visit 5 | A chemotactic cytokine which plays a role in the inflammatory process through the regulation of monocytes/macrophages | ClinicalTrials.gov |
Outcomes 0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as | Source |
|---|
Results by group 0
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units | Source |
|---|
Participant flow 0
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted | Source |
|---|
Adverse events 0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events | Source |
|---|
Adverse event totals 0
The totals the trial posted for each group.
| Total | Group | Affected | At risk | Source |
|---|
Papers 28
The papers the trial lists on ClinicalTrials.gov.
| PMID | Listed as | Source |
|---|---|---|
| 9525362 | BACKGROUND | PubMed |
| 10369305 | BACKGROUND | PubMed |
| 19944539 | BACKGROUND | PubMed |
| 20139996 | BACKGROUND | PubMed |
| 20609722 | BACKGROUND | PubMed |
| 20858956 | BACKGROUND | PubMed |
| 21345170 | BACKGROUND | PubMed |
| 21474666 | BACKGROUND | PubMed |
| 23251749 | BACKGROUND | PubMed |
| 23371369 | BACKGROUND | PubMed |
| 23592557 | BACKGROUND | PubMed |
| 23732272 | BACKGROUND | PubMed |
| 23964211 | BACKGROUND | PubMed |
| 25352800 | BACKGROUND | PubMed |
| 25859906 | BACKGROUND | PubMed |
| 26064288 | BACKGROUND | PubMed |
| 26580833 | BACKGROUND | PubMed |
| 27537541 | BACKGROUND | PubMed |
| 28302254 | BACKGROUND | PubMed |
| 28465805 | BACKGROUND | PubMed |
Grants 0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
| Project | Title | Principal investigators | Organization | Funder | Fiscal years | Source |
|---|
Trial comparisons 0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
| Comparison | Source |
|---|
Tests 4
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
| Test | Named as | Source |
|---|---|---|
| Stroop Color-Word Test | Primary outcome | ConductCognition |
| Symbol Coding | Primary outcome | ConductCognition |
| Trail Making Test A | Primary outcome | ConductCognition |
| Trail Making Test B | Primary outcome | ConductCognition |
Source 5
| Field | Value | Source |
|---|---|---|
| Release | trials-2026-11-12-0.4.0 | ClinicalTrials.gov |
| Release manifest SHA-256 | 0f4a8d8c48aee2a7573ae0fa94ecbeab70c1adbe449bbc95c424bc7d3e97b9d4 | ClinicalTrials.gov |
| Registry capture | 2026-11-12 | ClinicalTrials.gov |
| Results copy, AACT | 2026-03-23 | ClinicalTrials.gov |
| NIH clinical studies file | 2026-11-13 | ClinicalTrials.gov |
Release trials-2026-11-12-0.4.0
ClinicalTrials.gov's posted results, through CTTI's AACT: ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299 ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
ClinicalTrials.gov: none stated ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
NIH RePORTER's clinical studies and project files: Public domain (NIH RePORTER)